SCHEMBL2375746

SCHEMBL2375746

COCCN(C)C(=O)C(Cc1ccccc1)NCc1ccc(-c2ccccn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.44
MME P08473 1/20 0.42
SLC6A9 P48067 1/20 0.41
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSS P25774 1/20 0.40
MLNR O43193 1/20 0.40
NR1I2 O75469 1/20 0.40
SLCO2B1 O94956 1/20 0.40
ABCB11 O95342 1/20 0.40
ABCB1 P08183 1/20 0.40
UGT1A1 P22309 1/20 0.40
CCKAR P32238 1/20 0.40
OPRK1 P41145 1/20 0.40
GHSR Q92847 1/20 0.40
SLCO1B3 Q9NPD5 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
SLCO1B1 Q9Y6L6 1/20 0.40
ATR Q13535 2/20 0.40
HSD17B10 Q99714 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2375740 1.00 PPARG (0.44) PPARGMMESLC6A9CTSLCTSB
SCHEMBL2373930 0.87 GPR142 (0.46) PPARGMMECYP3A4CYP2D6CYP2C9
SCHEMBL2373927 0.87 GPR142 (0.46) PPARGMMECYP3A4CYP2D6CYP2C9
SCHEMBL2374783 0.85 PPARG (0.45) PPARGMMECTSLCTSBCTSS
SCHEMBL2374776 0.85 PPARG (0.45) PPARGMMECTSLCTSBCTSS
SCHEMBL2375171 0.83 MME (0.44) PPARGMMECTSLCTSBCTSS
SCHEMBL2375179 0.83 MME (0.44) PPARGMMECTSLCTSBCTSS
SCHEMBL1124614 0.82 ATM (0.51) PPARGCTSLCTSBCTSSMLNR
SCHEMBL1124616 0.82 ATM (0.51) PPARGCTSLCTSBCTSSMLNR
SCHEMBL2374270 0.76 L3MBTL1 (0.45) CTSLRAB9AMEN1MAPTTACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 PPARG 1076/4885MME 1117/4885SLC6A9 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.